{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:20:45Z","timestamp":1740140445945,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Ultrasonics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10396-020-01010-0","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T04:56:14Z","timestamp":1582952174000},"page":"299-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Application of the Z1071 criteria: classification of axillary lymph nodes on ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-0760","authenticated-orcid":false,"given":"Naoko","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol"},{"key":"1010_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA"},{"key":"1010_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"20","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;20:258\u201364.","journal-title":"J Clin Oncol"},{"key":"1010_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2214\/AJR.17.18295","volume":"210","author":"HT Le-Petross","year":"2018","unstructured":"Le-Petross HT, McCall LM, Hunt KK, et al. Axillary ultrasound identifies residual nodal diseases after chemotherapy: results from the American College of Surgeons Oncology Group Z1071 trial (Alliance). AJR Am J Roentgenol. 2018;210:669\u201376.","journal-title":"AJR Am J Roentgenol"},{"key":"1010_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2017.05.015","volume":"35","author":"A Peppe","year":"2017","unstructured":"Peppe A, Wilson R, Pope R, et al. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT). Breast. 2017;35:104\u20138.","journal-title":"Breast"},{"key":"1010_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2019.01.219","volume":"45","author":"R Di Micco","year":"2019","unstructured":"Di Micco R, Zuber V, Fiacco E, et al. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: time trend, imaging staging power and nodal downstaging according to molecular subtype. Eur J Surg Oncol. 2019;45:969\u201375.","journal-title":"Eur J Surg Oncol"},{"key":"1010_CR7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ejso.2018.10.001","volume":"45","author":"R Helfgott","year":"2019","unstructured":"Helfgott R, Mittlb\u0151ck M, Miesbauer M, et al. The influence of breast cancer subtypes on axillary ultrasound accuracy: a retrospective single center analysis of 583 women. Eur J Surg Oncol. 2019;45:538\u201343.","journal-title":"Eur J Surg Oncol"},{"key":"1010_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","volume":"20","author":"TJ Hieken","year":"2013","unstructured":"Hieken TJ, Boughey JC, Jones KN, et al. Imaging response and residual metastatic axillary lymph node diseases after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20:3199\u2013204.","journal-title":"Ann Surg Oncol"},{"key":"1010_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts LH, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 11). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"1010_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.breast.2016.11.012","volume":"31","author":"L Schwentner","year":"2017","unstructured":"Schwentner L, Helms G, Nekljudova B, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy-results from the multi-center SENTINA trial. Breast. 2017;31:202\u20137.","journal-title":"Breast"},{"key":"1010_CR11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","volume":"25","author":"O Kantor","year":"2018","unstructured":"Kantor O, Sipsy LM, Yao K, et al. A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2018;25:1304\u201311.","journal-title":"Ann Surg Oncol"},{"key":"1010_CR12","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-016-5277-1","volume":"23","author":"J Vila","year":"2016","unstructured":"Vila J, Mittendorf A, Farante G, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23:3501\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1010_CR13","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1097\/MD.0000000000001720","volume":"94","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim S, et al. Prognostic nomograms for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Medicine. 2015;94:e1720.","journal-title":"Medicine"},{"key":"1010_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clbc.2013.12.015","volume":"14","author":"RJ Schipper","year":"2014","unstructured":"Schipper RJ, Moossdorff M, Nelemans PJ, et al. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo (immuno) therapy in patients with clinically node-positive breast cancer. Clin Breast Cancer. 2014;14:315\u201322.","journal-title":"Clin Breast Cancer"},{"key":"1010_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-019-05214-y","volume":"176","author":"HJ Choi","year":"2019","unstructured":"Choi HJ, Ryu JM, Kim I, et al. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2019;176:591\u20136.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Medical Ultrasonics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-020-01010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10396-020-01010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-020-01010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:26:29Z","timestamp":1614471989000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10396-020-01010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s10396-020-01010-0","relation":{},"ISSN":["1346-4523","1613-2254"],"issn-type":[{"type":"print","value":"1346-4523"},{"type":"electronic","value":"1613-2254"}],"subject":[],"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Aruga has received honoraria from Chugai Pharmaceutical Co., Ltd. and Pfizer Japan Inc. Naoko Iwamoto, Shinichiro Horiguchi, Hiromi Miyamoto, and Yayoi Honda have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Ethics Committee of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital approved all experimental protocols, and written informed consent was waived because of the retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}